TrimRx's Blog

Wegovy delivers 15–20% body weight loss at one year in clinical trials. Real-world outcomes, plateau patterns, and maintenance strategies explained.

Wegovy is contraindicated in patients with active eating disorders or recent history due to risks of malnutrition, electrolyte imbalance, and

Wegovy body dysmorphia risk exists but affects fewer than 8% of users. Learn the warning signs, who’s most vulnerable, and how to mitigate psychological

Wegovy reduces binge eating episodes by 50-60% in clinical trials through slowed gastric emptying and central appetite suppression — mechanism explained.

Most patients lose 4–6 pounds in the first month on Wegovy — here’s the mechanism behind early results and what actually drives meaningful loss.

Wegovy reduces insulin resistance and androgen levels in PCOS patients, delivering 15–20% body weight reduction in clinical trials—here’s the protocol.

Wegovy during perimenopause addresses hormonal weight gain through GLP-1 receptor agonism that counteracts estrogen-driven metabolic shifts and insulin

Wegovy is not recommended for active Cushing’s syndrome due to cortisol-driven weight gain and metabolic dysfunction that oppose GLP-1 therapy mechanisms.

Compounded semaglutide contains the same active molecule as Wegovy but differs in FDA approval status, pricing, and manufacturing oversight—here’s what